TipRanks

Notifications

Prothena (PRTA) Gets a Buy Rating from JMP Securities

JMP Securities analyst Gobind Singh reiterated a Buy rating on Prothena (PRTAResearch Report) today and set a price target of $77.00. The company’s shares closed last Friday at $39.53.

According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.2% and a 21.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Kaleido Biosciences, and Seres Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prothena with a $76.00 average price target, a 107.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $79.75 and a one-year low of $10.72. Currently, Prothena has an average volume of 399.3K.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Read More on PRTA: